Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy. 2018

Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.

To explore whether integrated 18F-FDG PET/MRI can be used to predict pathological response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Between November 2014 and April 2016, 26 patients with breast cancer who had received NAC and subsequent surgery were prospectively enrolled. Each patient underwent 18F-FDG PET/MRI examination before and after the first cycle of NAC. Qualitative MRI parameters, including morphological descriptors and the presence of peritumoral oedema were assessed. Quantitatively, PET parameters, including maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis (TLG), and MRI parameters, including washout proportion and signal enhancement ratio (SER), were measured. The performance of the imaging parameters singly and in combination in predicting a pathological incomplete response (non-pCR) was assessed. Of the 26 patients, 7 (26.9%) exhibited a pathological complete response (pCR), and 19 (73.1%) exhibited a non-pCR. No significant differences were found between the pCR and non-pCR groups in the qualitative MRI parameters. The mean percentage reductions in TLG30% on PET and SER on MRI were significantly greater in the pCR group than in the non-pCR group (TLG30% -64.8 ± 15.5% vs. -25.4 ± 48.7%, P = 0.005; SER -34.6 ± 19.7% vs. -8.7 ± 29.0%, P = 0.040). The area under the receiver operating characteristic curve for the percentage change in TLG30% (0.789, 95% CI 0.614 to 0.965) was similar to that for the percentage change in SER (0.789, 95% CI 0.552 to 1.000; P = 1.000).The specificity of TLG30% in predicting pCR) was 100% (7/7) and that of SER was 71.4% (5/7). The sensitivity of TLG30% in predicting non-pCR was 63.2% (12/19) and that of SER was 84.2% (16/19). When the combined TLG30% and SER criterion was applied, sensitivity was 100% (19/19), and specificity was 71.4% (5/7). 18F-FDG PET/MRI can be used to predict non-pCR after the first cycle of NAC in patients with breast cancer and has the potential to improve sensitivity by the addition of MRI parameters to the PET parameters.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001578 Benzopyrans Compounds with a core of fused benzo-pyran rings. Benzopyran,Chromene,Chromenes
D015588 Observer Variation The failure by the observer to measure or identify a phenomenon accurately, which results in an error. Sources for this may be due to the observer's missing an abnormality, or to faulty technique resulting in incorrect test measurement, or to misinterpretation of the data. Two varieties are inter-observer variation (the amount observers vary from one another when reporting on the same material) and intra-observer variation (the amount one observer varies between observations when reporting more than once on the same material). Bias, Observer,Interobserver Variation,Intraobserver Variation,Observer Bias,Inter-Observer Variability,Inter-Observer Variation,Interobserver Variability,Intra-Observer Variability,Intra-Observer Variation,Intraobserver Variability,Inter Observer Variability,Inter Observer Variation,Inter-Observer Variabilities,Inter-Observer Variations,Interobserver Variabilities,Interobserver Variations,Intra Observer Variability,Intra Observer Variation,Intra-Observer Variabilities,Intra-Observer Variations,Intraobserver Variabilities,Intraobserver Variations,Observer Variations,Variabilities, Inter-Observer,Variabilities, Interobserver,Variabilities, Intra-Observer,Variabilities, Intraobserver,Variability, Inter-Observer,Variability, Interobserver,Variability, Intra-Observer,Variability, Intraobserver,Variation, Inter-Observer,Variation, Interobserver,Variation, Intra-Observer,Variation, Intraobserver,Variation, Observer,Variations, Inter-Observer,Variations, Interobserver,Variations, Intra-Observer,Variations, Intraobserver,Variations, Observer

Related Publications

Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
October 2009, European journal of nuclear medicine and molecular imaging,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
March 2024, Radiology. Imaging cancer,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
March 2022, Cancers,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
March 2013, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
July 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
January 2017, PloS one,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
December 2007, European journal of nuclear medicine and molecular imaging,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
July 2021, EJNMMI research,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
January 2014, Anticancer research,
Nariya Cho, and Seock-Ah Im, and Gi Jeong Cheon, and In-Ae Park, and Kyung-Hun Lee, and Tae-Yong Kim, and Young Seon Kim, and Bo Ra Kwon, and Jung Min Lee, and Hoon Young Suh, and Koung Jin Suh
August 2014, Anticancer research,
Copied contents to your clipboard!